Skip to main content
. 2018 Aug 16;8:12252. doi: 10.1038/s41598-018-29708-9

Figure 1.

Figure 1

miR-342-3p is down-modulated in TN tumors and associated to oncogenic features and poor clinical outcomes. (a) Heatmap and hierarchical clustering of miRNAs differentially expressed between TN tumors vs other phenotypes. (b) Pathway enrichment analysis of miRNAs-mRNAs altered in triple negative tumors. (c) RT-qPCR expression of miR-342-3p in breast cancer cell lines. The panel of cell lines showed a heterogeneous miR-342-3p expression with a significant down-modulation in basal A and B cell lines. Kruskal-Wallis test showed the statistical significance between the multiple phenotype comparisons. Expression level of miR-342-3p in (d) TCGA and (e) METABRIC databases across IHC subtypes, TN tumors: ER−, PR− Her2−, Her2 tumors: ER−, PR− and Her2+ and luminal tumors: ER/PR+ , Her2− or ER/PR+, Her2+ (f) Survival analysis according to miR-342-3p expression. Lower miR-342-3p expression levels is associated with a decreased overall survival in patients with triple negative breast cancer. Kaplan-Meier survival curve shows patients with lower miR-342-3p expression (≤1st quantile) in blue line and higher miR-342-3p expression (>to 1st quantile) in red line.